Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Cole

Sports Medicine Chicago, IL Medical Doctor

NPI 1659350379 CMS profile 301320

1611 W Harrison St, Ste 400, Chicago, IL 60612

Open in the dashboard

General payments

$2,062,389

752 records reported · program years 2019–2025

Research payments

$25,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$1,188,476

7 holdings reported · through program year 2025

Research they led as principal investigator

$840,502 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Brian Cole of Chicago, IL is reported in the CMS Open Payments database as having received $2,062,389 across 752 general payments and $25,500 in research payments paid to them. Separately, studies naming them as principal investigator received $840,502 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,188,476 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $474,355 99
2024 General $337,491 63
2023 General $256,604 94
2022 General $304,110 130
2021 General $294,970 93
2021 Research $25,500 1
2020 General $208,622 112
2019 General $186,237 161
2025 Ownership $148,306 1
2024 Ownership $148,306 1
2023 Ownership $182,091 1
2022 Ownership $182,091 1
2021 Ownership $182,091 1
2020 Ownership $182,091 1
2019 Ownership $163,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Cole
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Brian Cole were reported at $474,355. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Brian Cole Sports Medicine median Middle half National median
2019 $186,237 $1,176 $199–$4,249 $163
2020 $208,622 $708 $96–$2,890 $114
2021 $294,970 $1,213 $152–$3,994 $132
2022 $304,110 $1,230 $159–$3,998 $149
2023 $256,604 $584 $146–$2,836 $160
2024 $337,491 $628 $163–$3,168 $164
2025 $474,355 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $1,825,406 509 payments
  2. Djo, LLC $72,651 60 payments
  3. Vericel Corporation $35,734 45 payments
  4. Bioventus LLC $25,449 12 payments
  5. Smith+Nephew, Inc. $18,887 15 payments
  6. Pacira Pharmaceuticals Incorporated $14,207 6 payments
  7. Aesculap Biologics, LLC $14,107 36 payments
  8. Acumed LLC $13,375 12 payments
  9. Brixton Biosciences, Inc. $12,166 4 payments
  10. Endo Pharmaceuticals Inc. $5,489 6 payments
  11. Other $24,920 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $1,138,219 34 payments
  2. Consulting Fee $578,812 255 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $289,361 79 payments
  4. Travel and Lodging $34,954 159 payments
  5. Food and Beverage $11,509 216 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $6,050 4 payments
  7. Honoraria $3,300 1 payment
  8. Education $184 4 payments
Products named General payments · program years 2019–2025
  1. ARTHREX Biologics - Consumables - Cartilage Repair - Graftnet $650,100 16 payments
  2. Arthrex Upper Extremity - Implants - Biceps - FiberTak - Knotted $364,203 5 payments
  3. ARTHREX Knee & Hip - Instruments - Meniscal Repair - Zone Navigator $336,774 9 payments
  4. Arthrex Knee & Hip - Implants - Extra-Articular Lig & Patellofemoral - Knee FiberTak - Other $304,346 4 payments
  5. ARTHREX Shoulder - Implants - Biceps Repair - Fibertak $279,498 8 payments
  6. ARTHREX Shoulder - Implants - Biceps Repair - Fibertak $279,498 8 payments
  7. Arthrex Upper Extremity - Implants - Rotator Cuff - PushLocks - Knotless PK SP $244,489 3 payments
  8. Arthrex Upper Extremity - Implants - Rotator Cuff - CuffMend - FiberStitch $244,489 3 payments
  9. Arthrex Upper Extremity - Implants - Biceps - FiberTak $242,402 4 payments
  10. Arthrex Knee & Hip - Implants - Extra-Articular Lig & Patellofemoral - Knee FiberTak $242,402 4 payments
  11. Other $2,320,414 270 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $25,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

114

Median for Sports Medicine: 144

Drug cost

$1,279

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 32 $668
Meloxicam Generic 68 $355
Diclofenac Sodium Generic 14 $256

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$101,216

Of which drugs: $7,304

Medicare patients

354

Average age 72

Services billed

3,422

191 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 62%
Ischemic heart disease 23%
Cancer 18%
Diabetes 16%
Depression 15%
Chronic kidney disease 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 48 2,160 $213
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 15 $76

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

753 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record